Tuberculosis (TB) is a bacterial infection caused by a germ called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but they can also damage other parts of the body. TB spreads through the air when a person with TB of the lungs or throat coughs, sneezes or talks. If you think you have been exposed, you should go to your doctor for tests as soon as possible. You are more likely to get TB if you have a weak immune system.
Mycobacterium abscessus, a relative of the bacteria that cause tuberculosis and leprosy, is responsible for particularly severe damage to human lungs and can be resistant to many standard antibiotics, making infections extremely challenging to treat.
A new method that analyzes how individual immune cells react to the bacteria that cause tuberculosis could pave the way for new vaccine strategies against this deadly disease, and provide insights into fighting other infectious diseases around the world.
Scientists from the UK's University of Bath explore racemases - an important type of enzyme that is linked to certain cancers and other life-threatening diseases while also being critical to cell function - in a paper published in the prestigious journal Chemical Society Reviews. The scientists also propose new strategies for finding drugs that neutralize these enzymes.
Mycobacterium tuberculosis is remarkable because it can live in the human host for decades.
The immune response to tuberculosis (TB) differs in adults and newborn babies due to the way immune cells use energy to kick into gear in a bid to kill the bacteria. This fresh discovery - just published in leading journal, Frontiers in Immunology - offers hope for improving treatments for what remains a deadly disease.
A group of researchers from France, Germany, Belarus, Japan, and Russia and headed by a scientist from Skolkovo Institute of Science and Technology (Skoltech) has discovered how Mycobacterium tuberculosis survives in iron-deficient environments by using rubredoxin B (RubB)—a protein that belongs to the rubredoxin family and plays a significant role in adapting to varying environmental conditions.
AZoLifeSciences speaks to Dr. Gaspard Kerner about tuberculosis, and how ancient DNA could help us to further understand the immune system.
Scientists have discovered a key mechanism that enables dangerous bacteria to develop resistance to antibiotics.
In the course of a new and groundbreaking study, led by Dr, Natalia Freund and the doctoral candidate Avia Waston at the Sackler Medical Faculty, the research group succeeded in isolating monoclonal antibodies, which hindered the growth of tuberculosis germs in laboratory mice.
A significant class of heterocyclic compounds, called N-Aryl-C-nitroazoles, is used as fungicides and pesticides. But these substances could be harmful to human beings and cause mutations.
Kobe University and Sysmex Corporation have been engaged in joint research on the ELISPOT method, a new blood test for identifying the novel coronavirus disease (COVID-19).
Researchers from Johns Hopkins University and Medicine have designed a potential new antibiotic for a pathogen that is highly resistant to drugs and is often lethal to individuals suffering from lung diseases, including cystic fibrosis.
Throughout the pandemic, infectious disease experts and frontline medical workers have asked for a faster, cheaper and more reliable COVID-19 test.
Until recently, it was believed that the innate immune system, the body's first line of defense, lacked the ability to remember pathogens like the adaptive immune system.
Caring for people's health is a prescription for protecting rainforests, slowing climate change and creating significant monetary value, according to a new Stanford-led study.
A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has engineered powerful new antimicrobial molecules from toxic proteins found in wasp venom.
As Americans begin pulling up their sleeves for an annual flu vaccine, researchers at the University of Wisconsin-Madison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza.
Thomas Brück saw the sea whip Antillogorgia elisabethae for the first time 17 years ago while diving on a research trip to the Bahamas.
A study of older mice with type 2 diabetes has yielded highly promising results for researchers investigating potential new vaccines for tuberculosis (TB).
EKF Diagnostics Holdings plc, the AIM listed point-of-care business, announces that it has received an initial order worth £3 m from a partner from the private sector to supply PrimeStore MTM, a novel patented sample collection device, to be used in a COVID-19 testing programme for UK staff.